Document is current
Any future updates will be listed below
-
Authors
Levin, Noam
Kim, Sanghyun P https://orcid.org/0000-0001-9519-1994
Marquardt, Charles A
Vale, Nolan R
Yu, Zhiya
Sindiri, Sivasish https://orcid.org/0000-0003-2516-969X
Gartner, Jared J
Parkhurst, Maria
Krishna, Sri https://orcid.org/0000-0003-4994-3758
Lowery, Frank J https://orcid.org/0000-0002-4620-5293
Zacharakis, Nikolaos https://orcid.org/0000-0001-7103-5591
Levy, Lior
Prickett, Todd D
Benzine, Tiffany
Ray, Satyajit
Masi, Robert V
Gasmi, Billel
Li, Yong
Islam, Rafiqul
Bera, Alakesh
Goff, Stephanie L https://orcid.org/0000-0003-3317-9804
Robbins, Paul F https://orcid.org/0000-0002-1260-8123
Rosenberg, Steven A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00068003 at ClinicalTrials.govnct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
https://doi.org/10.1136/jitc-2025-013373
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers
https://doi.org/10.1136/jitc-2021-sitc2021.190
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
333 Neoantigen-specific stimulation for selective expansion of T-cell receptor engineered T cells with increased naïve or stem-like phenotypes
https://doi.org/10.1136/jitc-2025-sitc2025.0333
237 Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice
https://doi.org/10.1136/jitc-2022-sitc2022.0237
379 Selection of CD103+CD31-CD8+ cells enriches tumor reactivity of tumor infiltrating lymphocytes (TIL) independent of personalized sequencing
https://doi.org/10.1136/jitc-2025-sitc2025.0379
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
447 Clinical factors associated with growth and reactivity of tumor infiltrating lymphocytes for adoptive cell transfer in patients with metastatic epithelial cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0447
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
https://doi.org/10.1136/jitc-2022-006264
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
369 Concurrent neoantigen vaccination enhances the antitumor effect of dysfunctional T cells during cell therapy
https://doi.org/10.1136/jitc-2023-sitc2023.0369
nct03412877 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
https://doi.org/10.1136/jitc-2025-013373
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
333 Neoantigen-specific stimulation for selective expansion of T-cell receptor engineered T cells with increased naïve or stem-like phenotypes
https://doi.org/10.1136/jitc-2025-sitc2025.0333
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
https://doi.org/10.1136/jitc-2021-002873
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
https://doi.org/10.1136/jitc-2022-006264
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct00068003 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct00068003 at ClinicalTrials.govDocuments that mention this clinical trial
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
https://doi.org/10.1136/jitc-2025-013373
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers
https://doi.org/10.1136/jitc-2021-sitc2021.190
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
333 Neoantigen-specific stimulation for selective expansion of T-cell receptor engineered T cells with increased naïve or stem-like phenotypes
https://doi.org/10.1136/jitc-2025-sitc2025.0333
237 Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice
https://doi.org/10.1136/jitc-2022-sitc2022.0237
379 Selection of CD103+CD31-CD8+ cells enriches tumor reactivity of tumor infiltrating lymphocytes (TIL) independent of personalized sequencing
https://doi.org/10.1136/jitc-2025-sitc2025.0379
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
447 Clinical factors associated with growth and reactivity of tumor infiltrating lymphocytes for adoptive cell transfer in patients with metastatic epithelial cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0447
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
https://doi.org/10.1136/jitc-2022-006264
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
369 Concurrent neoantigen vaccination enhances the antitumor effect of dysfunctional T cells during cell therapy
https://doi.org/10.1136/jitc-2023-sitc2023.0369
nct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
https://doi.org/10.1136/jitc-2025-013373
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers
https://doi.org/10.1136/jitc-2021-sitc2021.190
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
333 Neoantigen-specific stimulation for selective expansion of T-cell receptor engineered T cells with increased naïve or stem-like phenotypes
https://doi.org/10.1136/jitc-2025-sitc2025.0333
237 Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice
https://doi.org/10.1136/jitc-2022-sitc2022.0237
379 Selection of CD103+CD31-CD8+ cells enriches tumor reactivity of tumor infiltrating lymphocytes (TIL) independent of personalized sequencing
https://doi.org/10.1136/jitc-2025-sitc2025.0379
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
447 Clinical factors associated with growth and reactivity of tumor infiltrating lymphocytes for adoptive cell transfer in patients with metastatic epithelial cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0447
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
https://doi.org/10.1136/jitc-2022-006264
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
369 Concurrent neoantigen vaccination enhances the antitumor effect of dysfunctional T cells during cell therapy
https://doi.org/10.1136/jitc-2023-sitc2023.0369
nct03412877 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
nct01174121 at ClinicalTrials.govDocuments that mention this clinical trial
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
https://doi.org/10.1136/jitc-2025-013373
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
333 Neoantigen-specific stimulation for selective expansion of T-cell receptor engineered T cells with increased naïve or stem-like phenotypes
https://doi.org/10.1136/jitc-2025-sitc2025.0333
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
https://doi.org/10.1136/jitc-2021-002873
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
https://doi.org/10.1136/jitc-2022-006264
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
Documents that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response
https://doi.org/10.1136/jitc-2025-014644
Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645
Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184
-
Funding
Funding for this research was provided by:
National Cancer Institute (N/A)
- License Information
